Page last updated: 2024-09-04

atazanavir sulfate and bilirubin

atazanavir sulfate has been researched along with bilirubin in 53 studies

Compound Research Comparison

Studies
(atazanavir sulfate)
Trials
(atazanavir sulfate)
Recent Studies (post-2010)
(atazanavir sulfate)
Studies
(bilirubin)
Trials
(bilirubin)
Recent Studies (post-2010) (bilirubin)
1,10224659025,9211,3375,871

Protein Interaction Comparison

ProteinTaxonomyatazanavir sulfate (IC50)bilirubin (IC50)
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)3.3884
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)1.3183

Research

Studies (53)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (22.64)29.6817
2010's38 (71.70)24.3611
2020's3 (5.66)2.80

Authors

AuthorsStudies
Chando, TJ; Dehal, SS; Everett, DW; Humphreys, WG; Patten, CJ; Zhang, D1
Christensen, AR; Furtek, KJ; Hale, BR; Jones, LE; Petersen, K; Riddle, MS; Tasker, SA1
Dellamonica, P1
Gold, J; Jeganathan, S; Smith, D1
Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Hill, A; Maitland, D; Moyle, G; Nelson, M; Pozniak, A1
Josephson, F; Karlström, O; Sönnerborg, A1
Burger, DM; Cleijsen, RM; de Wolf, F; Gras, L; Koopmans, PP; Kroon, FP; Lunel, FV; van de Ende, ME1
Blanco, A; Clotet, B; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M1
Abdel-Kader, L; Camacho, A; Lozano, F; Macías, J; Palacios, R; Pineda, JA; Rivero, A; Santos, J1
Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP1
Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E1
Barreiro, P; González, M; Gonzalez-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E1
Andersson, MC; Böttiger, Y; Flamholc, L; Gisslén, M; Hagberg, L; Josephson, F; Ormaasen, V; Sönnerborg, A; Vesterbacka, J1
Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Prosperi, M; Ragazzoni, E1
Choe, KW; Choe, PG; Jeon, JH; Kim, HB; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, KH1
Burger, DM; Dekker, D; Dorresteijn, MJ; Heemskerk, S; Pijnenburg, M; Rasing-Hoogveld, A; Smits, P; Wagener, FA1
Bellón, JM; González, MI; José, MI; Larru, B; Mellado, MJ; Muñoz-Fernández, MÁ; Navarro, ML; Nso Roca, AP; Nso, AP; Ramos, JT1
Barassi, A; Bini, T; Biondi, ML; Casana, M; Cicconi, P; d'Arminio Manforte, A; d'Eril, GM; Marchetti, GC; Pateri, F; Turri, O1
Alvarez, E; Cuenca, L; González-Lahoz, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E1
Casado, JL; Dronda, F; Hermida, JM; Hernandez-Novoa, B; Moreno, A; Moreno, S; Perez-Elias, MJ; Quereda, C; Rodriguez, JM; Rodriguez, MA1
Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S1
Azria, E; Crenn-Hebert, C; Ferreira, C; Floch-Tudal, C; Herinomenzanahary, E; Mandelbrot, L; Mazy, F; Meier, F; Peytavin, G; Treluyer, JM1
Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N1
Abelö, A; Ashton, M; Clewe, O; Flamholc, L; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Sönnerborg, A1
Agnes, G; Basso, RP; de Almeida, S; Kuhmmer, R; Lazzaretti, RK; Mattevi, VS; Pinheiro, CA; Ribeiro, JP; Silveira, JM; Silveira, MF; Sprinz, E; Turatti, L1
Carman, T; Hileman, C; Labbato, DE; Longenecker, C; McComsey, G; Milne, G; Storer, Nj; White, C1
Adorni, F; Bonora, S; Clementi, E; Di Perri, G; Ferraris, L; Galli, M; Gervasoni, C; Milani, G; Peri, A; Riva, A; Tarkowski, M; Viganò, O1
Bissio, E; Espinola, L; Gadano, A; Gallego, P; Lopardo, G; Stambullian, M1
Collier, AC; Daar, ES; Fischl, MA; Haas, DW; Mollan, K; Morse, GD; Ribaudo, HJ; Sax, PE; Tierney, C1
Äbelö, A; Ashton, M; Barrail-Tran, A; Bergstrand, M; Calcagno, A; D'Avolio, A; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Tarning, J; Vigan, M1
Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X1
Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Karolia, Z; Moyle, G; Ringner-Nackter, L; Seymour, N; Yapa, MH1
Chang, JH; Cheong, J; Ho, Q; Lin, M; Plise, E1
Bertz, R; Botes, M; Conradie, F; Eley, T; Hardy, H; Huang, SP; Josipovic, D; McGrath, D; Osiyemi, O; Zorrilla, CD1
Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL1
Apesteguia, AF; Domeque, N; Lozano, R1
Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I1
Antoniadou, A; Detsika, M; Hatzakis, A; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Paraskevis, D; Petrikkos, G; Protopapas, K; Sypsa, V1
Daar, ES; Haas, DW; Johnson, DH; McLaren, PJ; Morse, GD; Ritchie, MD; Venuto, C1
Beckman, JA; Goldfine, AB; Milian, J; Parmer, C; Zuflacht, JP1
Ando, A; Baumer, Y; Byron, MM; Chow, D; Kallianpur, KJ; Keating, S; Kohorn, L; Ndhlovu, L; Shikuma, C; Souza, S1
Colella, E; Di Cristo, V; Franzetti, M; Galli, M; Giacomelli, A; Oreni, L; Ridolfo, AL; Rusconi, S1
Berenguer, J; Blanco, JR; Estrada, V; Gómez-Garre, MD; Martínez, E; Masiá, M; Monge, S; Portilla, J; Sobrino, P; Viladés, C1
Durante, W; Durante, ZE; Liu, XM; Peyton, KJ1
Listowsky, I; Roy-Chowdhury, J; Roy-Chowdhury, N; Wolkoff, AW1
Broadhurst, R; Gugsa, S; Heller, T; Hosseinipour, MC; Lim, R; Ngongondo, M; Ongubo, DM; Phiri, S; Speight, C; Stanley, CC; Tembo, P; Tweya, H1
Ard, KL; Beckman, JA; Milian, J; Prenner, JC; Price, CN; Sax, PE; Solomon, DA; Wood, BR; Zuflacht, JP1
Baker, P; Chirwa, S; Erdem, H; Haas, DW; Leger, P; Leonard, M; Nwogu, JN; Olson, L; Richardson, DM; Turner, M1
Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B1
Becker, KJ; Budoff, M; Burkholder, GA; Chow, FC; Crane, HM; Delaney, JAC; Drozd, DR; Eron, JJ; Geng, E; Heckbert, SR; Ho, EL; Huffer, A; Hunt, PW; Kalani, R; Kim, HN; Kitahata, MM; Mathews, WC; Moore, RD; Nance, RM; Ritchings, C; Rosenblatt, L; Saag, MS; Tirschwell, DL; Whitney, BM; Wood, BR; Zunt, JR1
Chan, WW; Li, M; Zucker, SD1
Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M1
Chikamoto, J; Hirata, M; Nagahara, M; Omori, H; Otoi, T1

Reviews

1 review(s) available for atazanavir sulfate and bilirubin

ArticleYear
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
    Archives of toxicology, 2008, Volume: 82, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic

2008

Trials

15 trial(s) available for atazanavir sulfate and bilirubin

ArticleYear
Early clinical experience with atazanavir in treatment-experienced patients.
    Sexual health, 2006, Volume: 3, Issue:1

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; New South Wales; Oligopeptides; Pyridines; Treatment Outcome; Viral Load

2006
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2007
The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus.
    Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:2

    Topics: Acetylcholine; Aged; Atazanavir Sulfate; Bilirubin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Oligopeptides; Oxidative Stress; Pyridines; Vasodilation; Vasodilator Agents; von Willebrand Factor

2011
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome

2011
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    The AAPS journal, 2011, Volume: 13, Issue:4

    Topics: Atazanavir Sulfate; Bilirubin; Biomarkers; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines

2011
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Prospective Studies; Pyridines; Treatment Outcome; Triglycerides

2012
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:3

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Fasting; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Serum

2013
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
    The Journal of infectious diseases, 2013, Feb-01, Volume: 207, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Genetic Variation; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Ritonavir

2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides

2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Bilirubin; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Young Adult; Zinc Sulfate

2013
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:10

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Ritonavir

2013
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
    HIV medicine, 2014, Volume: 15, Issue:6

    Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides

2014
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Female; Genome-Wide Association Study; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Ritonavir

2014
Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.
    Acta diabetologica, 2015, Volume: 52, Issue:4

    Topics: Adult; Antioxidants; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Blood Pressure; Cardiovascular System; Cholesterol, LDL; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Vasodilation

2015
Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Viral Load

2017

Other Studies

37 other study(ies) available for atazanavir sulfate and bilirubin

ArticleYear
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
    Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:11

    Topics: Atazanavir Sulfate; Bilirubin; Dose-Response Relationship, Drug; Drug Interactions; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Kinetics; Microsomes, Liver; Oligopeptides; Pyridines; Recombinant Proteins

2005
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
    AIDS (London, England), 2005, Oct-14, Volume: 19, Issue:15

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Retrospective Studies; Treatment Outcome; Viral Load

2005
Can boosted atazanavir induce hyperlipotrophy?
    The Journal of infection, 2006, Volume: 52, Issue:6

    Topics: Aged; Atazanavir Sulfate; Bilirubin; Female; Hepatitis C; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Protease Inhibitors; Pyridines

2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:8

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Statistics, Nonparametric

2006
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation; Netherlands; Oligopeptides; Plasma; Pyridines; Retrospective Studies; Treatment Outcome

2007
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:5

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir

2007
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:4

    Topics: Adult; Age Factors; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines; Ritonavir; Transaminases

2008
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir

2008
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
    AIDS (London, England), 2008, Nov-30, Volume: 22, Issue:18

    Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Bilirubin; Drug Interactions; Female; Glucuronosyltransferase; Hepacivirus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ribavirin

2008
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:4

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Bilirubin; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load

2010
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    HIV medicine, 2010, Volume: 11, Issue:5

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load

2010
Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jul-01, Volume: 51, Issue:1

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Female; Gene Frequency; Genes, MDR; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Korea; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; Sequence Analysis, DNA; Severity of Illness Index

2010
HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2011, Volume: 48, Issue:1

    Topics: Adolescent; Adolescent Health Services; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Child; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Oligopeptides; Pyridines; Spain

2011
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.
    Journal of acquired immune deficiency syndromes (1999), 2011, Mar-01, Volume: 56, Issue:3

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; Humans; Male; Middle Aged; Oligopeptides; Plasma; Polymorphism, Genetic; Pyridines

2011
Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:10

    Topics: Adult; Alleles; Atazanavir Sulfate; Bilirubin; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Follow-Up Studies; Glucuronosyltransferase; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Odds Ratio; Oligopeptides; Pyridines; Regression Analysis; Retrospective Studies; RNA, Viral; ROC Curve; Viral Load

2011
The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; End Stage Liver Disease; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines

2011
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
    European journal of obstetrics, gynecology, and reproductive biology, 2011, Volume: 157, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cohort Studies; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Jaundice, Neonatal; Male; Maternal-Fetal Exchange; Medical Records; Oligopeptides; Phototherapy; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Pyridines; Retrospective Studies; Ritonavir

2011
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
    AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13

    Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides

2011
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Brazil; Cross-Sectional Studies; Female; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Male; Oligopeptides; Predictive Value of Tests; Pyridines; Risk Factors; Severity of Illness Index

2012
Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy.
    HIV medicine, 2012, Volume: 13, Issue:10

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Blood Flow Velocity; Brachial Artery; C-Reactive Protein; Cell Adhesion Molecules; Cross-Sectional Studies; Endothelium, Vascular; F2-Isoprostanes; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; HIV Protease Inhibitors; HIV Seropositivity; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Oligopeptides; Oxidative Stress; Pyridines; Retrospective Studies; Tumor Necrosis Factor-alpha; Vasodilation

2012
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    The AAPS journal, 2013, Volume: 15, Issue:2

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Computer Simulation; Drug Monitoring; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Nomograms; Oligopeptides; Pyridines; Reproducibility of Results; Ritonavir

2013
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
    Molecular pharmaceutics, 2013, Aug-05, Volume: 10, Issue:8

    Topics: Atazanavir Sulfate; Bilirubin; Cell Line; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indinavir; Liver-Specific Organic Anion Transporter 1; Models, Biological; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Solute Carrier Organic Anion Transporter Family Member 1B3

2013
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
    Xenobiotica; the fate of foreign compounds in biological systems, 2014, Volume: 44, Issue:3

    Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides

2014
Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:2

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; Drug Therapy, Combination; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Male; Models, Theoretical; Oligopeptides; Polymorphism, Genetic; Pyridines; Young Adult

2014
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
    International journal of STD & AIDS, 2014, Volume: 25, Issue:12

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cross-Sectional Studies; Glucuronosyltransferase; Greece; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Pyridines; Ritonavir

2014
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin.
    AIDS (London, England), 2016, Feb-20, Volume: 30, Issue:4

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Carotid Intima-Media Thickness; Female; HIV Infections; Humans; Male; Retrospective Studies

2016
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Antiviral research, 2016, Volume: 129

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load

2016
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
    HIV medicine, 2016, Volume: 17, Issue:9

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Biomarkers; Cyclopropanes; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Oxidative Stress; Peroxidase; Phospholipases A2; Plasma; Prospective Studies

2016
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
    Free radical biology & medicine, 2016, Volume: 94

    Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone

2016
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
    Clinical pharmacology in drug development, 2017, Volume: 6, Issue:2

    Topics: Animals; Atazanavir Sulfate; Bilirubin; Cells, Cultured; Female; Glucuronosyltransferase; Glutathione Transferase; Hepatocytes; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Rats, Wistar; Ritonavir; Substance-Related Disorders

2017
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    BMC infectious diseases, 2017, 07-03, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Malawi; Male; Medication Adherence; Middle Aged; Ritonavir; Treatment Failure; Urban Health; Viral Load

2017
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
    Pharmacogenetics and genomics, 2018, Volume: 28, Issue:1

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Black or African American; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; Humans; Jaundice; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; White People

2018
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
    The Journal of antimicrobial chemotherapy, 2018, 04-01, Volume: 73, Issue:4

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load

2018
Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
    Journal of acquired immune deficiency syndromes (1999), 2019, 08-15, Volume: 81, Issue:5

    Topics: Adult; Atazanavir Sulfate; Bilirubin; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Myocardial Infarction; United States

2019
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
    Journal of the American Heart Association, 2020, 10-20, Volume: 9, Issue:19

    Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors

2020
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
    BioMed research international, 2022, Volume: 2022

    Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome

2022
Evaluating variations in bilirubin glucuronidation activity by protease inhibitors in canine and human primary hepatocytes cultured in a 3D culture system.
    Toxicology in vitro : an international journal published in association with BIBRA, 2023, Volume: 93

    Topics: Animals; Atazanavir Sulfate; Bilirubin; Dogs; Hepatocytes; Humans; Liver; Protease Inhibitors; Ritonavir; Spheroids, Cellular

2023